Umirolimus

Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used agent-eluting stent (DES) applications[1].

Product Specifications

CAS Number

[851536-75-9]

UNSPSC

12352005

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/umirolimus.html

Concentration

10mM

Purity

99.35

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N2[C@](CCCC2)([H])C(O[C@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@H](C[C@@]3([H])O[C@@](C1=O)([C@@H](CC3)C)O)OC)\C)C)C)=O)OC)O)\C)C)=O)([H])[C@H](C)C[C@H]4C[C@H]([C@@H](CC4)OCCOCC)OC)=O

Molecular Formula

C55H87NO14

Molecular Weight

986.28

References & Citations

[1]Eberhard Grube, et al. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices. 2006 Nov;3 (6) :731-41.